Jubrail Dahabreh
- Biological Psychiatry top 10%
- Immunology top 10%
- Immunotherapy and Immune Responses 3
- Oncology top 10%
- Lung Cancer Research Studies 7
- Cancer Immunotherapy and Biomarkers 5
-
- Lung Cancer Treatments and Mutations 6
- Lung Cancer Diagnosis and Treatment 3
-
- Neuroblastoma Research and Treatments 4
-
- Cancer Genomics and Diagnostics 4
-
- Neuroendocrine Tumor Research Advances 3
Jubrail Dahabreh
26 papers receiving 601 citations
Peers
Comparison fields: 5 of 65
- Biological Psychiatry 45
- Immunology 274
- Oncology 348
- Pulmonary and Respiratory Medicine 191
- Behavioral Neuroscience 12
Countries citing papers authored by Jubrail Dahabreh
This map shows the geographic impact of Jubrail Dahabreh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jubrail Dahabreh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jubrail Dahabreh more than expected).
Fields of papers citing papers by Jubrail Dahabreh
This network shows the impact of papers produced by Jubrail Dahabreh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jubrail Dahabreh. The network helps show where Jubrail Dahabreh may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Jubrail Dahabreh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 5 | |
| 2 | 2015 | 20 | |
| 3 | 2012 | 6 | |
| 4 | 2012 | 12 | |
| 5 | MAGRIT phase III trial in adjuvant NSCLC: MAGE-A3 gene expression frequency on the first 2150 patients screened and demographics of first patients randomized | 2009 | 2 |
| 6 | 2009 | 11 | |
| 7 | 2008 | 17 | |
| 8 | GENE EXPRESSION SIGNATURE IS A POTENTIAL PREDICTIVE FACTOR FOR EFFICACY OF MAGE-A3 ANTIGEN-SPECIFIC CANCER IMMUNOTHERAPEUTIC (ASCI) AS ADJUVANT THERAPY IN RESECTED STAGE IB/II NON-SMALL CELL LUNG CANCER (NSCLC) | 2008 | 2 |
| 9 | 2008 | 23 | |
| 10 | 2008 | 22 | |
| 11 | 2007 | 6 | |
| 12 | 2007 | 72 | |
| 13 | 2007 | 3 | |
| 14 | 2006 | 4 | |
| 15 | 2004 | 1 | |
| 16 | 2003 | 5 | |
| 17 | 2003 | 34 | |
| 18 | 2003 | 1 | |
| 19 | 2000 | 29 | |
| 20 | 1998 | 15 |
About Jubrail Dahabreh
Jubrail Dahabreh is a scholar working on Oncology, Biological Psychiatry and Pulmonary and Respiratory Medicine, having authored 28 papers that have together received 615 indexed citations. Recurring topics across this work include Lung Cancer Research Studies (7 papers), Lung Cancer Treatments and Mutations (6 papers), Cancer Immunotherapy and Biomarkers (5 papers), Neuroblastoma Research and Treatments (4 papers), Cancer Genomics and Diagnostics (4 papers), Neuroendocrine Tumor Research Advances (3 papers), Immunotherapy and Immune Responses (3 papers) and Lung Cancer Diagnosis and Treatment (3 papers). The work is most often cited by research in Biological Psychiatry (45 citations), Immunology (274 citations) and Oncology (348 citations). Jubrail Dahabreh has collaborated with scholars based in Greece, Poland and Spain. Frequent co-authors include Charalambos Zisis, M. Zieliński, Konstantinos I. Gourgoulianis, Vincent Brichard, Tõnu Vanakesa, Jacek Jassem, Johan Vansteenkiste, A. Linder, Bernward Passlick and Frédéric Lehmann. Their work appears in journals such as Journal of Thoracic Oncology, European Journal of Cardio-Thoracic Surgery, Lung Cancer, Annals of Oncology and Cancer Biology & Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.